A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Lipid Panel with LDL Cholesterol
研究概览
简要总结
The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.
详细描述
Clozapine is renowned for its efficacy in treating schizophrenia refractory to typical or atypical antipsychotics. Though the effectiveness of clozapine has been established, a considerable number of patients with schizophrenia are partially responsive or unresponsive to clozapine. In addition, long-term use of clozapine is associated with the development of obsessive-compulsive symptoms and metabolic syndrome. In order to overcome these short-comings and to increase efficacy, aripiprazole augmentation was implemented. Quantitative electroencephalogram will be used to monitor the occurrence of abnormal findings and to analyze the changes in electroencephalographic pattern with linear and non-linear methodology.
Comparisons: Design of double-blind randomized placebo controlled study of patients at Refractory Schizophrenia Clinique in Department of Neuropsychiatry at Seoul National University Hospital.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, 18-65 years of age.
- •Patients must have a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
- •Female patients of menarche must be using a medically accepted means of contraception (e.g. oral contraceptives, Depo-Provera, abstinence).
- •Each patient must provide written informed consent after full explanation of study protocol, and authorized legal guardian must understand the nature of the study and must also give assent to study participation.
- •Patients must have a baseline (day 0) BPRS score of at least 35 or over 2 of 5 SANS global rating item scores of at least
- •Patients have been receiving clozapine treatment for more than 1 year and there has been no change in clozapine dosage for more than 3 months.
- •Patients must have a history of antipsychotic treatment with at least 2 different kinds prior to clozapine administration.
- •Subjects who are fluent in Korean.
排除标准
- •DSM-IV substance (except nicotine or caffeine) dependence within the past 1 year.
- •Female patients who are either pregnant or lactating.
- •Mental retardation (IQ < 70).
- •Neurological disorders including epilepsy, stroke, or severe head trauma.
- •Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, urinalysis and EKG.
- •Prior history of aripiprazole non-response or intolerance.
- •BPRS score of < 35 and over 4 of 5 SANS global rating item scores of <
- •Participation in a clinical trial of another investigational drug within 3 months (90 days) prior to study entry.
- •Treatment with an injectable depot neuroleptic within less than three dosing interval between the last depot neuroleptic injections and baseline (day 0).
- •History of electroconvulsive therapy within the past 3 months.
- •Subjects who are not fluent in Korean.
研究组 & 干预措施
A
clozapine plus aripiprazole
干预措施: aripiprazole (Drug)
B
clozapine plus placebo
干预措施: placebo (Drug)
结局指标
主要结局
Lipid Panel with LDL Cholesterol
时间窗: one year
FBS-PP & HbA1c
时间窗: one year
Brief Psychotic Rating Scale (BPRS): Measure of efficacy will be changes in BPRS total and subscale scores from baseline to 8th week endpoint. Follow-up evaluation will be made every 6th month till 1 year after 8th week end point.
时间窗: one year
Schedule for Assessment of Negative Symptoms (SANS): Measure of efficacy will be changes in SANS total and subscale scores from baseline to 8th week endpoint. Follow-up evaluation will be made at 6 month and 12 month after 8th week end point.
时间窗: one year
Serum Prolactin Level
时间窗: one year
Body Mass Index & Abdominal Circumference
时间窗: one year
次要结局
- Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS)(one year)
- Serum Clozapine Level(one year)
- Clinical Global Impression-Severity & Improvement (CGI-S & CGI-I)(one year)
- Montgomery-Asberg Depression Rating Scale (MADRS)(one year)
- Yale-Brown Obsessive Compulsive Scale (YBOCS)(one year)
- Subjective Well-being under Neuroleptics scale (SWN)(one year)
- Udvalg Fur Kliniske Undersogesler (UKU)(one year)
- Admission Battery, CBC, & EKG(one year)
- Blood Pressure and Pulse Rate(one year)
- Quantitative Electroencephalogram(one year)